Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary comput... Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. Mehr anzeigen
- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of...
- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease...
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in...
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial...
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in...
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.490196078431 | 2.04 | 2.18 | 1.84 | 1223476 | 1.98593748 | CS |
| 4 | 0.24 | 13.4078212291 | 1.79 | 3.755 | 1.79 | 5558484 | 2.31136547 | CS |
| 12 | -0.1 | -4.69483568075 | 2.13 | 3.755 | 1.52 | 2091243 | 2.23924799 | CS |
| 26 | 0.82 | 67.7685950413 | 1.21 | 3.83 | 1 | 4267509 | 2.1863329 | CS |
| 52 | -3.74 | -64.8180242634 | 5.77 | 7.68 | 1 | 2389791 | 2.20141571 | CS |
| 156 | -11.08 | -84.5156369184 | 13.11 | 16.1671 | 1 | 855633 | 2.56958727 | CS |
| 260 | 1.9776 | 3774.04580153 | 0.0524 | 33.99 | 0.0524 | 608817 | 2.96800596 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
